Should doctors reconsider standard gout treatments? The primary mechanism of hyperuricemia in patients with gout is inadequate renal uric acid excretion, but the standard recommendation for uric acid-lowering therapy (ULT) is xanthine oxidase inhibition (XOI), which helps lower blood uric acid levels in affected individuals regardless of the cause of the hyperuricemia. However, a new clinical trial reported in the journal Arthritis & Rheumatology suggests that a drug that has received less attention, benzbromarone, may work better at lower doses.
Researchers conducted a prospective, randomized, single-center, open-label trial of men with gout and inadequate renal uric acid excretion (defined as partial excretion of urate
The results showed that more participants in the LDBen group than in the LDFeb group met the serum urate target (61% versus 32%, p
Compared to LDFeb, LDBen has superior uric acid-lowering effects and a similar safety profile in relatively young and healthy patients with renal uric acid-deficient gout.
The authors write, "The results suggest that low-dose benzbromarone may merit more consideration as a safe and effective therapy to achieve blood uric acid goals for gout control."
Read the paper to learn more about.
https://onlinelibrary.wiley.com/doi/10.1002/art.42266
